181 related articles for article (PubMed ID: 8104043)
1. Autonomic effects of clozapine in schizophrenia: comparison with placebo and fluphenazine.
Zahn TP; Pickar D
Biol Psychiatry; 1993 Jul 1-15; 34(1-2):3-12. PubMed ID: 8104043
[TBL] [Abstract][Full Text] [Related]
2. Neuroleptic effects on autonomic activity in schizophrenia: between-group and within-subject paradigms and comparisons with controls.
Zahn TP; Pickar D; van Kammen DP
Schizophr Bull; 2001; 27(3):503-15. PubMed ID: 11596851
[TBL] [Abstract][Full Text] [Related]
3. Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia.
Owen RR; Gutierrez-Esteinou R; Hsiao J; Hadd K; Benkelfat C; Lawlor BA; Murphy DL; Pickar D
Arch Gen Psychiatry; 1993 Aug; 50(8):636-44. PubMed ID: 8343034
[TBL] [Abstract][Full Text] [Related]
4. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine.
Pickar D; Owen RR; Litman RE; Konicki E; Gutierrez R; Rapaport MH
Arch Gen Psychiatry; 1992 May; 49(5):345-53. PubMed ID: 1375019
[TBL] [Abstract][Full Text] [Related]
5. The brain metabolic patterns of clozapine- and fluphenazine-treated patients with schizophrenia during a continuous performance task.
Cohen RM; Nordahl TE; Semple WE; Andreason P; Litman RE; Pickar D
Arch Gen Psychiatry; 1997 May; 54(5):481-6. PubMed ID: 9152102
[TBL] [Abstract][Full Text] [Related]
6. Neuroleptic effects on electrodermal responsivity to soft tones and loud noise in schizophrenia.
Green MF; Nuechterlein KH
Psychiatry Res; 1988 Apr; 24(1):79-86. PubMed ID: 2899332
[TBL] [Abstract][Full Text] [Related]
7. The relationship of symptomatology and medication to electrodermal activity in schizophrenia.
Green MF; Nuechterlein KH; Satz P
Psychophysiology; 1989 Mar; 26(2):148-57. PubMed ID: 2567035
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular autonomic reactivity in schizophrenics under neuroleptic treatment: A potential predictor of short-term outcome?
Agelink MW; Malessa R; Kamcili E; Zeit T; Lemmer W; Bertling R; Klieser E
Neuropsychobiology; 1998; 38(1):19-24. PubMed ID: 9701718
[TBL] [Abstract][Full Text] [Related]
9. Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia.
Zahn TP; Pickar D; Haier RJ
Schizophr Res; 1994 Sep; 13(2):133-44. PubMed ID: 7986770
[TBL] [Abstract][Full Text] [Related]
10. Symptomatology and electrodermal activity as predictors of neuroleptic response in young male schizophrenic inpatients.
Lindström EM; Ohlund LS; Lindström LH; Ohman A
Psychiatry Res; 1992 May; 42(2):145-58. PubMed ID: 1352902
[TBL] [Abstract][Full Text] [Related]
11. Clozapine as a first treatment for schizophrenia.
Woerner MG; Robinson DG; Alvir JM; Sheitman BB; Lieberman JA; Kane JM
Am J Psychiatry; 2003 Aug; 160(8):1514-6. PubMed ID: 12900316
[TBL] [Abstract][Full Text] [Related]
12. Is clozapine response different in neuroleptic nonresponders vs partial responders?
Osser DN; Albert LG
Arch Gen Psychiatry; 1990 Feb; 47(2):189-90. PubMed ID: 1967927
[No Abstract] [Full Text] [Related]
13. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response.
Breier AF; Malhotra AK; Su TP; Pinals DA; Elman I; Adler CM; Lafargue RT; Clifton A; Pickar D
Am J Psychiatry; 1999 Feb; 156(2):294-8. PubMed ID: 9989566
[TBL] [Abstract][Full Text] [Related]
14. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine.
Litman RE; Su TP; Potter WZ; Hong WW; Pickar D
Br J Psychiatry; 1996 May; 168(5):571-9. PubMed ID: 8733795
[TBL] [Abstract][Full Text] [Related]
15. Type I and type II schizophrenia: relations between tonic electrodermal activity and clinical ratings before and after haloperidol treatment.
Maina G; Barzega G; Bellino S; Bogetto F; Ravizza L
Psychiatry Res; 1995 Jun; 57(1):49-56. PubMed ID: 7568558
[TBL] [Abstract][Full Text] [Related]
16. Quantitative effects of typical and atypical neuroleptics on smooth pursuit eye tracking in schizophrenia.
Litman RE; Hommer DW; Radant A; Clem T; Pickar D
Schizophr Res; 1994 May; 12(2):107-20. PubMed ID: 8043521
[TBL] [Abstract][Full Text] [Related]
17. Electrodermal and vascular orienting response in schizophrenic patients: relationship to symptoms and medication.
Schlenker R; Cohen R; Hubmann W; Mohr F; Wahlheim C; Watzl H; Werther P
Eur Arch Psychiatry Clin Neurosci; 1995; 245(3):152-8. PubMed ID: 7669822
[TBL] [Abstract][Full Text] [Related]
18. A systematic review of the evidence of clozapine's anti-aggressive effects.
Frogley C; Taylor D; Dickens G; Picchioni M
Int J Neuropsychopharmacol; 2012 Oct; 15(9):1351-71. PubMed ID: 22339930
[TBL] [Abstract][Full Text] [Related]
19. Effects of clozapine on heart rate dynamics and their relationship with therapeutic response in treatment-resistant schizophrenia.
Kim JH; Yi SH; Lee J; Kim YS
J Clin Psychopharmacol; 2013 Feb; 33(1):69-73. PubMed ID: 23277266
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of clozapine partial responders with conventional antipsychotics.
Rajarethinam R; Gilani S; Tancer M; DeQuardo J
Schizophr Res; 2003 Mar; 60(1):97-8. PubMed ID: 12505145
[No Abstract] [Full Text] [Related]
[Next] [New Search]
